Citations

Clear

948 citation(s) found for "Li, Bryan".

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD
Bodansky, Aaron, Ahyong, Vida , Dayao, Monica, Asaki, James , Vanasupa, ShiLu, Dandekar, Ravi , Chen, Shini, Sabatino, Joe, Klauer, Sam, Knudsen, Giselle, Valenzuela, Carlos Lizama, Mccutcheon, Krista, Zorn, Kelsey, Sidhu, Sukhman, Yu, David, Garcia, Samantha, Quandt, Zoe, Wang, Chung-Yu, Rojas, Bryan Castillo, Tilton, Iris, Citron, Y. Rose, Sharathchandra, Akshay, Gerungan, Chloe, Tomko, Stuart, McKeon, Andrew, Cooper, Tiffany, Harms, Meagan, Fancy, Stephen P J, Green, A J, Caliskan, Ilay , Cadwell, Cathryn R., Ostrem, Bridget EL, Karalius, Mary, Braun, Lindsay, Gupta, Sasha , Francisco, Carla, Peng, Greta, Reddy, A. O., Nash, Kendall, Mandel‐Brehm, Caleigh , Arnold, Thomas D. , Anderson, Mark S., Gerdts, Josiah, DeRisi, Joseph L., Bodansky, Aaron , Dayao, Monica T. , Knudsen, Giselle M. , Quandt, Zoe , Castillo-Rojas, Bryan , Citron, Y. Rose, Tomko, Stuart R. , Robbins, Nathaniel M. , McKeon, Andrew , Cooper, Tiffany P. , Harms, Meagan, Gomez, Refujia , Fancy, Stephen P.J. , Cadwell, Cathryn René , Ostrem, Bridget E.L. , Braun, Lindsay C., Francisco, Carla , Peng, Greta Solinap , Reddy, Alyssa , Pleasure, Samuel J , Anderson, Mark S. , Wilson, Michael R. , DeRisi, Joseph L

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.06.722823 | PMID 42182119 Get It

Autoimmune diseases arise when B and T lymphocytes lose tolerance to self. Yet in most disorders, the underlying molecular determinants, including autoantibodies, epitopes and lymphocyte clones that drive tissue injury remain undefined. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD) is a rare and often fatal pediatric neuroendocrine syndrome with strong evidence of antigen-driven paraneoplastic autoimmunity, including association with the intracellular autoantigen ZSCAN1. However, the effector immune circuit and the epitope-level determinants operating within the hypothalamus and brainstem have remained unknown. To address this challenge in ROHHAD and more broadly in autoimmune disease, we developed the Autoimmune Epitope and immunoGlobulin/Immune-receptor identification System (AEGIS), an integrated framework that links immune repertoires to their cognate self-epitopes. AEGIS combines B cell and T cell receptor profiling from sites of tissue injury with high-resolution epitope mapping, direct sequencing of antigen-specific autoantibodies, in silico antibody-antigen folding, selection, and T cell antigen discovery. Applied to a deeply phenotyped child with ROHHAD, AEGIS revealed a compartmentalized, clonally restricted immune response in which brain-deposited IgG and expanded cerebrospinal fluid B cell and CD4 T cell clonotypes converged on shared ZSCAN1 epitopes, resolved to minimal determinants and peptide-MHC ligands. These findings provide a clone- and epitope-linked mechanistic map of ROHHAD autoimmunity and establish a generalizable framework for identifying candidate pathogenic clones and antigens across diverse autoimmune diseases.
Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial
Zuchelkowski, Benjamin E. , Inman, Kyle, Nouraie, S Mehdi, Beru, Neeharika, Naqvi, Asma , Qin, Shulin, Yeh, Calvin H., Zhang, Yingze , Shah, Faraaz , Sharma, Lokesh , Zhang, Lianghui , Morris, Alison, Kim, Paul Y., Jacobs, Jana L. , Nouraie, Mehdi , Inman, Kyle W , Nouraie, Seyed Mehdi , Shah, Faraaz A , Zhang, Lianghui , McVerry, Bryan J , Morris, Alison , Neal, Matthew D , Seheult, Jansen N , Kitsios, Georgios D , Mellors, John W , Lawrence, Daniel A , Kim, Paul Y , Jacobs, Jana L , Bain, William G , Zhang, Yingze , Inman, Kyle , Naqvi, Asma , Qin, Shulin , Yeh, Calvin H., Sharma, Lokesh , Dela Cruz, Charles S , Seheult, Jansen N.

Mayo Clinic

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047693 | PMID 42089155 Get It

Background COVID‐19 and other respiratory viral infections can cause cardiovascular complications. SARS‐CoV‐2 virions are found in the blood, and circulating viral RNA levels are associated with death. We hypothesized that viremia can induce thrombotic endotheliopathy that contributes to death and studied this relationship in patients hospitalized for COVID‐19 and enrolled in the ACTIV‐4a (Accelerating COVID‐19 Therapeutic Interventions and Vaccines) randomized trial of antithrombotic therapy. Methods We quantified SARS‐CoV‐2 nucleocapsid RNA and protein in plasma and measured their associations with clinical outcomes and biomarkers of thromboinflammation and endotheliopathy. We used Cox regression and Fine–Gray competing risk models to analyze survival and thrombosis. We conducted causal mediation analysis to explore whether thrombotic endotheliopathy mediates the relationship between viral RNA and death. Results In 93 patients, SARS‐CoV‐2 RNA and N‐antigen were higher in nonsurvivors. Baseline viral RNA levels were associated with increased 90‐day death (hazard ratio [HR], 1.31 [95% CI, 1.17–1.46]) and thrombosis (HR, 1.35 [95% CI, 1.24–1.47]). Viral RNA more effectively predicted survivorship than N‐antigen levels. Soluble thrombomodulin, a biomarker of thrombotic endotheliopathy, positively correlated with viral RNA levels. Mediation analysis revealed that soluble thrombomodulin accounts for 12.2% (95% CI, 0.1%–32.3%; P =0.048) after adjustment for age and sex of the relationship between viral RNA and the 90‐day mortality rate. Conclusions Elevated plasma SARS‐CoV‐2 RNA levels are associated with death in ACTIV‐4a, which is causally mediated in part by soluble thrombomodulin. We propose that lung–blood viral dissemination is a potential mechanism for cardiovascular complications of respiratory viruses. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04505774.
Clinical Utility of the Moving Valgus Stress Test and Milking Maneuver for Medial Ulnar Collateral Ligament Injuries of the Elbow
Sciascia, Aaron D. , Chalmers, Peter, Smith, Matthew V. , Griffith, Timothy B. , Erickson, Brandon, Freehill, Michael T., Safran, Marc, Hardaway, Austin, Azar, Frederick M., Brolin, Tyler, Spence, David, Jones, Grant, Freehill, Michael T. , Sciascia, Aaron , Camp, Christopher L. , Griffith, Timothy Bryan , Freehill, Michael T , Bowman, Eric N. , Chalmers, Peter N. , Wolf, Brian R. , Safran, Marc R. , Azar, Frederick M. , Brolin, Tyler J. , Spence, David D. , Cox, Charles L. , LeClere, Lance E. , Jones, Grant

Mayo Clinic

The American Journal of Sports Medicine | May 6, 2026 | Volume: 54 | Issue: 8 | Pages: 1993-2002

10.1177/03635465261439107 | PMID 42087694 Get It

Background: Several special tests for detecting medial ulnar collateral ligament (MUCL) injuries of the elbow have been described, but data on the clinical utility of these tests are limited. Purpose: To determine the clinical utility of selected elbow special tests to detect MUCL injuries in an athletic population. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 84 consecutive patients with sports-related elbow pain underwent a standardized clinical examination. Overall, 6 special tests (moving valgus stress test, static valgus stress test, modified valgus stress test, milking maneuver, pronation flexion resistance test, and temple/cheek press test) were performed. Sensitivity, specificity, accuracy, positive/negative predictive value, and positive/negative likelihood ratio (LR+ and LR–, respectively) were calculated for individual tests and combinations of tests to detect MUCL injuries. Higher values for the LR+ and lower values for the LR– represent stronger clinical utility. Results: For detecting MUCL injuries, the moving valgus stress test resulted in the highest sensitivity (98%) and accuracy (93%) with the lowest LR– (2%). The milking maneuver had the highest LR+ (5.1) with the second highest sensitivity (77%) and accuracy (79%). The pronation flexion resistance test and the temple/cheek press test had the lowest LR+ (1.5 and 1.8, respectively) and highest LR– (94% and 95%, respectively) in addition to the lowest sensitivity (16% and 9%, respectively) and accuracy (33% and 30%, respectively). No combination of tests resulted in increased clinical utility. Conclusion: The moving valgus stress test and milking maneuver demonstrated acceptable clinical utility in which the moving valgus stress test was better for ruling out MUCL injuries and the milking maneuver was better at ruling in MUCL injuries. There was no added value when combining the 2 tests together or with other maneuvers.
Comparative Efficacy of Standalone Ab‐Interno Canaloplasty Versus Ab‐Interno Canaloplasty Combined With Phacoemulsification: A Systematic Review and Meta‐Analysis
Wong, Hon Jen , Sheng, Jiankai, Anggreni, Devy, Yeong, Trevor J., Lim, Sheng Yang , Betzler, Bjorn Kaijun , Ang, Bryan Chin Hou, Betzler, Bjorn K , Yeong, Trevor James Jun‐Ming, Ang, Bryan C H

Mayo Clinic

Clinical & Experimental Ophthalmology | May 5, 2026 | Volume: 54 | Issue: 5 | Pages: 678-686

10.1111/ceo.70124 | PMID 42086211 Get It

ABSTRACT Background Ab‐interno canaloplasty (ABiC) may be performed as a standalone procedure or in combination with phacoemulsification (ABiC+Phaco). This study aims to examine the comparative surgical outcomes of both procedures. Methods PubMed, EMBASE and CENTRAL were searched for randomised controlled trials, cohort studies and retrospective case series published from inception to 31 March 2025 that compared outcomes of standalone ABiC and ABiC+Phaco in the treatment of open‐angle glaucoma (OAG). Random‐effects meta‐analysis was performed to pool the mean difference in intraocular pressure (IOP) and glaucoma medications compared to baseline. Results Eight studies with a pooled total of 663 eyes were included in final analysis. There was no significant difference in IOP‐lowering efficacy between ABiC+Phaco and standalone ABiC across all timepoints (6 months, 1 year, 2 years and 3 years) with a mean difference of 0.25 mmHg (95% CI: −0.98 to 1.48) at 3 years. There was also no significant difference in glaucoma medication reduction between ABiC+Phaco and standalone ABiC across all timepoints, with a mean difference of 0.03 medication reduction (95% CI: −0.18 to 0.23) at 3 years. A small IOP‐lowering benefit of ABiC+Phaco versus standalone ABiC in primary OAG‐only studies (mean difference 0.75 mmHg, 95% CI: 0.03–1.47) was observed at 3 years. Conclusion Our meta‐analysis suggests that phacoemulsification may not offer significant additional IOP and glaucoma medication reduction to standalone ABiC. However, results should be interpreted with caution due to a moderate risk of bias across all included studies. Regardless, our findings are consistent with existing literature on the effect of adjunctive phacoemulsification on other ab‐interno MIGS.
Mutation-specific NPM1 immunohistochemistry is a sensitive method for detecting residual disease in mid- and postinduction bone marrows: comparison of NPM1 immunohistochemistry, NPM1 real-time polymerase chain
Hong, Ellie, Bailey, Nathanael G. , Davis, Katelynn, Matsumoto, Nana , Rea, Bryan, Aggarwal, Nidhi , Monaghan, Sara A. , Jawad, Majd, Aggarwal, Nidhi , Monaghan, S A , Hong, Ellie S. , Moore, Erika M. , Rea, Bryan A. , Jawad, Majd

Mayo Clinic

American Journal of Clinical Pathology | May 5, 2026 | Volume: 165 | Issue: 6 | Pages: No page available

10.1093/ajcp/aqag062 | PMID 42309046 Get It

Abstract Objectives Per National Comprehensive Cancer Network guidelines for acute myeloid leukemia (AML), bone marrow (BM) evaluation is recommended after starting induction chemotherapy at 14 to 21 days (mid-induction) and 30 to 35 days (postinduction). Timely assessment of residual morphologic and molecular disease is challenging at these time points, given the low cellularity, the lack of CD34 or CD117 expression by blasts in most NPM1-mutated (NPM1mut) AML, and the longer turnaround time for molecular testing. Methods NPM1 mut AML undergoing BM evaluation at mid- and postinduction with concurrent flow cytometry and NPM1 real-time polymerase chain reaction or next-generation sequencing was evaluated. Different cell types positive by NPM1 immunohistochemistry (IHC) were enumerated, and the results were compared with flow cytometry and molecular findings. Results NPM1 IHC demonstrated a sensitivity of 78% and 41% for detecting residual mutation at mid- and postinduction, respectively, with a positive predictive value ranging from 88% to 100%. Of 16 IHC-negative cases, 3 had no residual NPM1 mutation, 12 had very low-level mutation at a variant allele frequency of less than or equal to 21 transcripts, and only 1 had a high-level mutation in a markedly hypocellular BM. Of 24 IHC-positive cases, 22 had residual NPM1 mutation, and 2 showed false-positive staining in only a single cell with no residual NPM1 mutation. The level of IHC staining was mostly proportional to the level of residual mutation. Conclusions Mutation-specific NPM1 IHC is a valuable tool for a rapid assessment of residual morphologic and molecular disease in mid- and postinduction NPM1mut AML.
AI-based discovery of functional boundaries in the human brain from intraoperative electrophysiology
Leszek, Simon, Baker, Matthew , Klassen, Bryan T. , Jensen, Michael A. , Valencia, Gaby Ojeda, Müller, Klaus‐Robert , Miller, Kai J. , Baker, Matthew R , Jensen, Michael A

Mayo Clinic

No container title available | May 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.02.26352297 | PMID 42145648 Get It

Abstract Neurosurgical and neuromodulation therapies such as deep brain stimulation (DBS) require millimeter-level accuracy to effectively target functional brain regions. Yet, many neuroanatomical boundaries remain invisible to current imaging and electrophysiology methods, limiting precision and contributing to suboptimal patient outcomes. Here, we introduce a self-supervised artificial intelligence (AI) framework that learns to delineate functional subregions directly from the spectral content of intraoperative local field potential (LFP) recordings, without the need for predefined biomarkers or anatomical labels. The framework identifies physiologic structure across the full spectrum of the signal and, through explainable AI (XAI), reveals the specific frequency components underlying these distinctions. Validated in the subthalamic nucleus (STN), the model aligned with clinically defined borders and rediscovered known beta oscillations. Applied to the motor thalamus in tremor patients, it consistently identified functional transitions corresponding to the ventral oralis posterior (Vop) and ventral intermediate (Vim) nuclei—regions where conventional methods fail to provide reliable boundaries. To assess clinical relevance, physiologically defined clusters were functionally evaluated using monopolar review data at their first DBS clinic postoperative visit, demonstrating distinct stimulation-response profiles across clusters and linking electrophysiologic segmentation to clinically meaningful programming outcomes. These findings demonstrate that intraoperative LFP recordings can be transformed into both a real-time guidance resource and a data-driven platform for biomarker discovery, establishing a foundation for more precise, individualized neuromodulation therapies and advancing our understanding of functional brain organization.
Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience
Rael, Sofia , Neth, Bryan J. , Johnson, Derek, Sosa, Santiago Martinez, Mathis, Ganiru O, Uhm, Joon H. , Ruff, Michael W. , Kizilbash, Sani H, Campian, Jian L, Giannini, Caterina, Schultz, Sydney Ellen, Jaeckle, Kurt, Sherman, Wendy, Mrugala, Maciej M, Galloway, Taylor, Breen, William G. , Lehrer, Eric J. , Jenkins, RB , Sener, Ugur, Johnson, Derek R. , Sener, Uğur , Lachance, Daniel H , Johnson, Derek R , Lachance, Daniel , Jaeckle, Kurt A , Galloway, Taylor M, Breen, Will , Sener, Ugur , Neth, Byran J. , Sosa, Santiago Martinez , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Giannini, Caterina , Parney, Ian F. , Burns, Terry C. , Schultz, Sydney E, Jaeckle, Kurt A. , Mrugala, Maciej , Galloway, Taylor , Drucker, Kristen , Jenkins, Robert B.

Mayo Clinic

Neuro-Oncology Practice | April 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/nop/npag037 | PMID 42750887 Get It

Abstract Background Isocitrate dehydrogenase (IDH)-mutant gliomas are infiltrative tumors with limited treatment options at recurrence. Early studies suggest IDH inhibition has therapeutic activity. We evaluated clinical outcomes associated with IDH-1 inhibitor ivosidenib in recurrent IDH-1-mutant gliomas and molecular predictors of response. Methods We retrospectively analyzed adults treated with ivosidenib from January 2021 to August 2025 with predominantly recurrent, pretreated CNS WHO grade 2-4 astrocytoma IDH-mutant or grade 2-3 oligodendroglioma, IDH-mutant and 1p/19q codeleted. Prior anticancer treatments, toxicities, enhancement status at ivosidenib initiation, and genomic alterations were collected. The primary endpoint was progression-free survival (PFS); secondary analyses evaluated associations between PFS, genomic complexity, and CDKN2A/B homozygous deletion. Results Ninety-two adults, median age 43, were included: 61 astrocytomas and 31 oligodendrogliomas, mostly grade 2. Before ivosidenib, 69 had surgery, 64 chemotherapy, and 64 radiation. Median time from diagnosis to ivosidenib was 4.8 years, with median of two prior progressions. Median treatment duration was 5.8 months. Median PFS was 15.2, 4.6, and 2.1 months for astrocytoma grades 2-4, 14.0 and 6.9 months for oligodendroglioma grades 2-3. Increasing genomic complexity was associated with shorter PFS in univariate analysis. Patients without CDKN2A/B homozygous deletion had median PFS of 19.2 months. Two patients with homozygous deletion had median PFS of 0.6 months. Conclusions In this retrospective analysis of predominantly recurrent IDH-1-mutant glioma, ivosidenib was associated with longer PFS in lower-grade, non-enhancing tumors that received little or no prior anticancer treatment and less complex genomic profiles. These findings support a context-dependent benefit of IDH inhibition in recurrent disease.
Summative Report on Time Out of Play and Injury Rates for Major and Minor League Baseball: An Analysis of 83,215 Injuries From 2011 to 2023
Ward, Gavin H. , Meta, Fabien , Cabarcas, Brandon , Hebert, Elizabeth, Griffith, Timothy B. , Meister, Keith, Camp, Christopher L. , Cabarcas, Brandon C. , Griffith, Timothy Bryan

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 7 | Pages: 1738-1746

10.1177/03635465261434005 | PMID 41981906 Get It

Background: Recent reports suggest increasing trends in injuries, primarily among pitchers and upper extremity injuries, among Major League Baseball (MLB) and Minor League Baseball (MiLB) players. Accordingly, an updated comprehensive report on injury epidemiology in professional baseball is needed. Purpose: To (1) update the literature with a comprehensive epidemiological report of all injuries in MLB and MiLB; (2) provide a detailed breakdown of characteristics of the top 50 injuries; and (3) analyze long-term trends in injuries and days missed (DM) over time. Study Design: Case Series; Level of evidence, 4. Methods: The MLB Health and Injury Tracking System was used to identify injuries in MLB and MiLB players from 2011 to 2023. The inclusion criteria consisted of injuries occurring during spring training, regular season, or postseason activities that resulted in ≥1 DM from play. Basic and advanced player and injury characteristics were analyzed—including a list of the top 50 most common injuries. Results: From 2011 to 2023, a total of 83,215 musculoskeletal injuries occurred among MLB and MiLB players, resulting in 1,280,887 total DM, with a mean (median) DM per injury of 18 (11). The upper extremity accounted for 46% of injuries, and the lower extremity for 30%. The most common injury was hamstring strains (n = 6603; 7.9%); hamate fractures had the highest rate of surgery (81%); and elbow medial ulnar collateral ligament injury resulted in the highest DM (583,070 days). From 2011 to 2023, a significant increase was observed in the number of annual injuries (excluding 2020) ( P = .028) and injuries per game ( P = .003). However, 2018 and 2019 saw the highest number of injuries, and injuries did not rise after 2020. Conclusion: The annual number of injuries and rate of injuries per game increased significantly from 2011 to 2023; however, injuries did not increase over the final 3 years of the study (2021 to 2023). The percentage of overall injuries was dominated by upper extremity injuries among pitchers, although hamstring strains were the most common injury type overall.
A Collaborative Initiative to Improve Anaphylaxis Management in Utah Schools
Witt, Bryan , Wright, Benjamin L. , Witt, Bryan S, Wright, Benjamin L

Mayo Clinic

Pediatrics | April 15, 2026 | Volume: 157 | Issue: 5 | Pages: No page available

10.1542/peds.2025-073978 | PMID 41980724 Get It

Food allergies are a significant public health concern in the United States. Fatality from food-induced anaphylaxis is associated with delayed administration of epinephrine. Utah children were at increased risk for school-related anaphylaxis due to a lack of school nurses, adequately trained staff, and a standardized approach to food allergy emergency management. In collaboration with the Utah School Nurses Association, the Utah Food Allergy Network, and the Utah Department of Health & Human Services, among other contributors, we aimed to accomplish the following goals: (1) develop and implement a web-based curriculum to train school staff to recognize and respond to anaphylaxis in school settings; (2) educate school officials on existing legal protections for layperson first responders; and (3) facilitate acquisition of unassigned epinephrine for use in schools through existing charitable pharmaceutical programs. From 2012 to 2023, our training program was completed 5759 times by individuals representing 421 Utah schools. The course was most frequently completed by teachers (n = 3006, 52.2%), office staff (n = 1480, 25.7%), and principals (n = 276, 4.8%). Since 2015, we have maintained an average year-to-year retention rate of greater than 68%. We observed a 245% increase in the number of schools with unassigned epinephrine. Due to this intervention, many Utah schools now prepare employees to administer epinephrine in the case of anaphylactic emergencies. Although school nurses play a significant role, their coverage is inadequate to meet the needs of all students at risk for anaphylaxis. Training volunteers to recognize and respond to anaphylaxis in school settings is needed to reduce delays in treatment and improve outcomes.